You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The French bioinformatics and genomic services company will help Dana-Farber manage clinical research data for the cancer center's new interpretive genomics program.
A single-cell RNA sequencing analysis suggests progression to multiple myeloma involves shifts in immune cell representation and activity in the microenvironment.
A more accurate, integrated risk model for pancreatic cancer included not only clinical risk factors, but also blood markers and pancreatic cancer loci from genome-wide association studies.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
The protein-protein interactions tallied in the project are expected to inform future studies of biology and disease in various tissue and cell types.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.
In a new study, using larger numbers of patient-specific mutations helped better detect residual disease in breast cancer patients' blood after treatment.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.